進行前立腺癌に対する内分泌化学療法

Abstract

進行前立腺癌40症例に対する内分泌化学療法の治療成績を, 同時期に内分泌療法単独で治療された23症例の治療成績と比較検討した.1)内分泌化学療法群の初回治療後の奏効率は内分泌療法単独群より優れていた.2)再燃は5/40例で, 内分泌療法単独群の再燃率より有意に低く, かつ再燃までの期間も平均20ヵ月で, 内分泌療法単独群の11ヵ月より長かった.3)副作用はCDDP投与に伴う嘔気, 嘔吐がおもなもので, 骨髄抑制の程度は軽く重篤なものはなかった

From November 1984 to April 1989, 40 patients with advanced prostate cancer were treated with chemohormonal therapy consisting of orchiectomy, diethylstilbestrol diphosphate, CDDP and cyclophosphamide. Of the 40 patients, 23 had partial response, 15 had stable disease and 2 had progression of disease at 3 months after the initiation of the treatment. In analysis of survival rate, the 5-year survival rate of all cases was 61.5%. The prognosis of the patients with low grade tumors was better than those with high grade tumors. In stages C and D patients, the survival rate was 75%, and 56%, respectively. Relapse occurred in 5 patients. The interval between start of treatment and relapse was approximately 20 months. Relapse rate was lower than that of 23 patients treated with hormonal treatment alone during the same periods (p less than 0.05). Gastrointestinal symptoms including different degrees of nausea and vomiting were observed in about half of the patients. Myelosuppression was seen in a few cases. These findings suggest the effectiveness of chemohormonal therapy for newly diagnosed advanced prostate cancer.